We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+23.6%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$138M
AUM Growth
-$12.5M
Cap. Flow
-$25.1M
Cap. Flow %
-18.28%
Top 10 Hldgs %
79.11%
Holding
58
New
8
Increased
6
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.9M
2
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$1.82M
3
CFRX
ContraFect Corporation
CFRX
+$942K
4
QGEN icon
Qiagen
QGEN
+$701K
5
GOSS icon
Gossamer Bio
GOSS
+$604K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$69.5M
2
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$1.4M
3
EQM
EQM Midstream Partners, LP
EQM
+$1.39M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$604K
5
DERM
Dermira, Inc.
DERM
+$345K

Sector Composition

Rank Sector Weight
1 Healthcare 94.64%
2 Energy 1.7%
3 Consumer Staples 0.09%
4 Materials 0.06%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$50M 36.33%
778,585
+731,585
+1,557% +$41.9M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$36.9M 26.83%
218,380
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$5.91M 4.3%
55,000
– –
QDEL icon
4
QuidelOrtho
QDEL
$1.19B
$3.67M 2.66%
48,844
– –
OXFD
5
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.83M 2.05%
170,303
– –
VRML
6
DELISTED
Vermillion, Inc.
VRML
$2.61M 1.9%
3,221,933
– –
BMY.RT
7
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$2.11M 1.53%
+699,648
New +$1.82M
CFRX
8
DELISTED
ContraFect Corporation
CFRX
$1.75M 1.28%
3,534
+3,250
+1,144% +$942K
EQM
9
DELISTED
EQM Midstream Partners, LP
EQM
$1.54M 1.12%
51,250
-50,000
-49% -$1.39M
KPTI icon
10
Karyopharm Therapeutics
KPTI
$216M
$1.53M 1.12%
5,333
+666
+14% +$144K
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$1.5M 1.09%
34,040
+18,000
+112% +$460K
BIIB icon
12
Biogen
BIIB
$30.4B
$1.48M 1.08%
5,000
– –
HROW icon
13
Harrow
HROW
$1.74B
$1.4M 1.02%
180,000
– –
VNDA icon
14
Vanda Pharmaceuticals
VNDA
$327M
$1.31M 0.95%
80,000
– –
AMRN
15
Amarin Corp
AMRN
$292M
$1.26M 0.92%
2,950
– –
MASI
16
DELISTED
Masimo
MASI
$1.26M 0.92%
8,000
– –
ARVN icon
17
Arvinas
ARVN
$517M
$1.23M 0.9%
30,000
– –
ALBO
18
DELISTED
Albireo Pharma Inc
ALBO
$1.22M 0.89%
48,000
+10,000
+26% +$200K
DERM
19
DELISTED
Dermira, Inc.
DERM
$1.21M 0.88%
80,000
-40,000
-33% -$345K
GTHX
20
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.06M 0.77%
40,000
– –
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.03M 0.75%
8,300
– –
ARNA
22
DELISTED
Arena Pharmaceuticals Inc
ARNA
$999K 0.73%
22,000
– –
XLRN
23
DELISTED
Acceleron Pharma
XLRN
$990K 0.72%
18,672
– –
CCXI
24
DELISTED
ChemoCentryx, Inc.
CCXI
$989K 0.72%
+25,000
New +$439K
IMGN
25
DELISTED
Immunogen Inc
IMGN
$919K 0.67%
180,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Birchview Capital held 58 positions worth $138M, down 8.3% from $150M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Birchview Capital withdrew a net $25.1M in Q4 2019, closing 6 positions and reducing 5 holdings. Its most notable exit was Celgene Corp, an estimated $69.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

Against the trend, Birchview Capital opened a new position in Bristol-Myers Squibb Company Contingent Value Rights worth $2.11M.

  • Birchview Capital's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 699,648 shares worth $2.11M.
  • Birchview Capital added most to Bristol-Myers Squibb in Q4 2019, an estimated $41.9M increase.
  • Birchview Capital's biggest Q4 2019 reduction was EQM Midstream Partners, LP, cutting an estimated $1.39M.
  • Birchview Capital fully exited Celgene Corp in Q4 2019, selling an estimated $69.5M.
  • Birchview Capital's ten largest holdings make up 79% of its $138M portfolio in Q4 2019.
  • Birchview Capital opened 8 new positions and closed 6 in Q4 2019.
  • Birchview Capital's portfolio value fell 8.3% quarter-over-quarter to $138M.

Based on Birchview Capital's 13F filing for Q4 2019, filed 12 Feb 2020.